Youguo Long

681 total citations
10 papers, 243 citations indexed

About

Youguo Long is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Youguo Long has authored 10 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 1 paper in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Youguo Long's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (4 papers). Youguo Long is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (4 papers). Youguo Long collaborates with scholars based in China and Hong Kong. Youguo Long's co-authors include Qiting Wu, Yao Yao, Peng Li, Ruocong Zhao, Jiang Lv, Diwei Zheng, Yangqiu Li, Suna Wang, Zhenfeng Zhang and Simiao Lin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and International Immunopharmacology.

In The Last Decade

Youguo Long

10 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Youguo Long China	8	209	125	69	53	46	10	243
Aodrenn Spill Switzerland	4	241 1.2×	137 1.1×	78 1.1×	46 0.9×	68 1.5×	6	300
Megan M. Dacek United States	8	147 0.7×	69 0.6×	66 1.0×	43 0.8×	63 1.4×	12	200
Purva Rathi United States	4	245 1.2×	123 1.0×	86 1.2×	63 1.2×	67 1.5×	4	282
Jiang Lv China	6	162 0.8×	90 0.7×	63 0.9×	37 0.7×	34 0.7×	8	225
Nicholas F. Kuhn United States	6	217 1.0×	163 1.3×	101 1.5×	57 1.1×	60 1.3×	6	314
Roseanna M. Petrovic United Kingdom	5	238 1.1×	104 0.8×	76 1.1×	65 1.2×	86 1.9×	8	282
Ying Fang United States	11	214 1.0×	129 1.0×	95 1.4×	26 0.5×	30 0.7×	17	298
Daniela Tantalo Australia	6	264 1.3×	133 1.1×	82 1.2×	84 1.6×	74 1.6×	11	304
Elizabeth Wickman United States	4	278 1.3×	143 1.1×	99 1.4×	43 0.8×	88 1.9×	4	313
Nils Wellhausen United States	7	213 1.0×	87 0.7×	117 1.7×	76 1.4×	50 1.1×	14	273

Countries citing papers authored by Youguo Long

Since Specialization

Citations

This map shows the geographic impact of Youguo Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youguo Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youguo Long more than expected).

Fields of papers citing papers by Youguo Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youguo Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youguo Long. The network helps show where Youguo Long may publish in the future.

Co-authorship network of co-authors of Youguo Long

This figure shows the co-authorship network connecting the top 25 collaborators of Youguo Long. A scholar is included among the top collaborators of Youguo Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youguo Long. Youguo Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Wang, Jiongliang, Linfu Zhou, Le Qin, et al.. (2025). DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity. Science Immunology. 10(105). eadm8251–eadm8251. 3 indexed citations

Zhou, Linfu, Diwei Zheng, Zhaoyang Tang, et al.. (2024). Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. SHILAP Revista de lepidopterología. 32(2). 200817–200817. 20 indexed citations

Qin, Le, Jiang Lv, Di Wu, et al.. (2023). The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer. International Immunopharmacology. 121. 110402–110402. 7 indexed citations

Lv, Jiang, Ruocong Zhao, Di Wu, et al.. (2022). Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Molecular Therapy — Oncolytics. 28. 46–58. 23 indexed citations

Li, Ming, Shanglin Li, Ruocong Zhao, et al.. (2022). CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer. Clinical and Experimental Medicine. 23(6). 2409–2419. 10 indexed citations

Zhao, Ruocong, Shanglin Li, Jiang Lv, et al.. (2021). Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer. Frontiers in Immunology. 12. 660488–660488. 50 indexed citations

Lin, Shouheng, Lin Cheng, Wei Ye, et al.. (2021). Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies. Frontiers in Immunology. 12. 642528–642528. 19 indexed citations

Wu, Di, Jiang Lv, Ruocong Zhao, et al.. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research. 8(1). 3–3. 34 indexed citations

Qin, Le, Ruocong Zhao, Xinru Wei, et al.. (2020). Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomarker Research. 8(1). 19–19. 51 indexed citations

10.

Zhao, Ruocong, Lin Cheng, Zhiwu Jiang, et al.. (2018). DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. OncoImmunology. 8(1). e1509173–e1509173. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact